OIS Podcast Update on Dry Eye and MGD - What's Up at J&J, Oyster Point and Tear Film Innovations?

05/23/18 • 15 min

OIS Podcast | Ophthalmology's leading Podcast

Hear the latest from OIS events as the OIS Podcast connects with Tom Frinzi and Joseph Boorady, the new leadership at Johnson & Johnson Vision. Next, CEO Jeffrey Nau introduces Oyster Point to OIS while Rob Thornhill, CEO of Tear Film Innovations, explains his company's treatment for Meibomian Gland Disorder.

Previous Episode

OIS Podcast Finds Out What's Next for Nicox and Zeiss in Two Talks with Michele Garufi and Jim Mazzo

Nicox has had quite a year, bringing two new ophthalmology projects to the market through partnerships with Bausch + Lomb and Eyevance Pharmaceuticals. So what's next for the global company? CEO Michele Garufi provides answers. James V. Mazzo, global president for Carl Zeiss Meditec's Strategic Business Unit Ophthalmic Devices, sits down with us at OIS@ASCRS to talk about his three years at the company and what the future might bring.

Next Episode

CEO Sean Ianchulev Shares Eyenovia's Plans to Replace Eye Drops with New Microdosing Technology

The last time we connected with Sean Ianchulev, MD, MPH, he shared Transcend's ultimately winning story. Now, he's the CEO and CMO of Eyenovia, a four-year-old company that's developing a line of therapeutics for Glaucoma, Dry Eye, Mydriasis, and Myopia. The company says its high-precision microdosing can deliver smaller doses with greater effect by uniformly coating the corneal surface rather than the conjunctiva to reduce collateral tissue exposure and focus on the cornea where 80% of intraocular drug penetration occurs. By reformulating generic compounds like latanaprost into microdose versions, Eyenovia is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. The company's delivery device also is able to track dosages, giving patients, physicians, and caregivers the ability to closely track when these therapies are delivered.